View all news

    Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

    05/21/2021
    Download(opens in new window)PDF 515 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com